Journals / Türkiye Diyabet ve Obezite Dergisi / 2022 / Cilt: 6 - Sayı: 1

Identifying the Risk Group for Insulin Therapy in Patients with Gestational Diabetes

Gestasyonel Diyabetli Hastalarda İnsülin Tedavisi İçin Riskli Grubun Belirlenmesi

Pages
59–66
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Closer follow-up is required for the patients found to be in the risk group for insulin therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: This study aims to determine the predictors of antenatal insulin therapy (AIT) in patients with gestational diabetes mellitus (GDM) who applied to the outpatient endocrine clinic of a tertiary hospital.
📊
Key Findings & Data:Material and Methods: The study included 619 patients with GDM.Oral glucose tolerance test (OGTT), HbA1c (%), lipid levels, and other biochemical measurements of two groups (patients with or without insulin use) were compared with Mann-Whitney U or Student t-test.
💡
Conclusion & Impact:Closer follow-up is required for the patients found to be in the risk group for insulin therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Gestasyonel diyabetes mellitus · Oral glukoz tolerans testi · İnsülin

Abstract

Aim: This study aims to determine the predictors of antenatal insulin therapy (AIT) in patients with gestational diabetes mellitus (GDM) who applied to the outpatient endocrine clinic of a tertiary hospital. Material and Methods: The study included 619 patients with GDM.Oral glucose tolerance test (OGTT), HbA1c (%), lipid levels, and other biochemical measurements of two groups (patients with or without insulin use) were compared with Mann-Whitney U or Student t-test. Demographic characteristics, obesity, and diet adherence were compared with the Chi-Square test. OGTT-75 measurements between the three insulin groups (basal, bolus or both uses) were compared with ANOVA. Results: In this study, 27.0% of the GDM patients needed insulin therapy. The insulin group had a significantly higher rate of obese, morbidly obese, and poor diet adherence patients than the MNT group and had significantly higher values measured in the 75-g OGTT (OGTT-75) for 0-h glucose, 2-h glucose, HbA1C (%), and triglyceride. In OGTT-75, all three measurement values (0-h, 1-h, 2-h glucose) above the cut-off were associated with insulin requirement. In OGTT-75, 2-h glucose value > 151.5 mg/dL (68.4% sensitivity and 60.0% specificity) predicted general need for insulin, and 0-h glucose value > 95.0 mg/dL (72.0% sensitivity and 69.0% specificity) predicted the need for basal AIT. Conclusion: We suggest identifying the risky group for insulin therapy at the time of diagnosis in GDM. Closer follow-up is required for the patients found to be in the risk group for insulin therapy.

Özet

Amaç: Bu çalışmanın amacı üçüncü basamak bir hastanenin endokrin polikliniğine başvuran gestasyonel diyabetes mellitus (GDM) tanılı hastaların antenatal insülin tedavisini (AIT) predikte eden değişkenleri tespit etmektir. Gereç ve Yöntemler: Çalışmaya GDM tanılı 619 hasta dahil edildi. İnsülin kullanan ve kullanmayan iki grubun oral glukoz tolerans testi (OGTT), HbA1C, lipid düzeyleri ve diğer biyokimyasal ölçümleri Mann-Whitney U veya Student t-testi ile karşılaştırıldı. Bu gruplar arasındaki demografik özellikler, obezite, HbA1c (%) ve diyete uyum Ki Kare testi ile karşılaştırıldı. Üç insülin grubu (bazal, bolus veya her ikisini kullanan) arasındaki OGTT-75 ölçümleri ANOVA ile karşılaştırıldı. Bulgular: Çalışmamıza dahil edilen GDM’li hastaların %27.0’sinde insülin ihtiyacı olmuştur. İnsülin grubunda; obez, morbid obez ve düşük diyet uyumu olan hasta oranı, ayrıca OGTT-75 0-s glukoz, 2-s glukoz, HbA1c (%) ve trigliserid ölçümleri MNT grubuna göre anlamlı olarak yüksek bulundu. OGTT-75' de üç ölçüm değerinin birden kesme değerin üstünde olması insülin ihtiyacı ile ilişkiliydi. OGTT-75 2-s glukoz değeri > 151.5 mg/dL (% 68.4 sensivite, % 60.0 spesifite) olması insülin ihtiyacını genel olarak predikte ederken, 0-s glukoz değerinin> 95.0 mg/dL (% 72.0 sensivite, %69.0 spesifite) olması bazal AIT ihtiyacını predikte etti. Sonuç: GDM’de tanı ile birlikte insülin tedavisi için riskli grubun belirlenmesini öneriyoruz. İnsülin tedavisi için risk grubunda bulunan hastalarda daha yakın takip gereklidir.

🔖

Cite This Article

COŞKUN, H., BİLGİNER, M. C., GÜNAY, Y. E., TÜFEKÇİ, D., NUHOĞLU, İ., ÜÇÜNCÜ, Ö., KOÇAK, M. (2022). Identifying the Risk Group for Insulin Therapy in Patients with Gestational Diabetes. Türkiye Diyabet ve Obezite Dergisi, Cilt: 6 - Sayı: 1, 59–66. https://ajindex.com/articles/627811

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Guariguata L, Linnenkamp U, Beagley J, Whiting DR, Cho NH. Global estimates of the prevalence of hyperglycaemia in pregnancy. Diabetes Res Clin Pract. 2014;103(2):176-185
  2. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet Gynecol. 2018;131(2):e49-e64
  3. ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus. Obstet Gynecol. 2018;132:e228-e248
  4. American Diabetes Association
  5. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S200-S210
  6. The Socıety of Endocrınology and Metabolısm of Turkey. Clinical Practice Guideline for Diagnosis, Treatment and Follow-up of Diabetes Mellitus and Its Complications - 2019. 178-183(12th Edition
  7. Harrison RK, Cruz M, Wong A, Davitt C, Palatnik A. The timing of initiation of pharmacotherapy for women with gestational diabetes mellitus. BMC Pregnancy Childbirth. 2020;20(1):773
  8. Asiedu-Danso M, Kretchy IA, Sekyi JK, Koduah A. Adherence to antidiabetic medications among women with gestational diabetes. J Diabetes Res. 2021;2021:9941538
  9. Sarbacker GB, Urteaga EM. Adherence to insulin therapy. Diabetes Spectr. 2016;29(3):166-170
  10. Benhalima K, Robyns K, Van Crombrugge P, Deprez N, Seynhave B, Devlieger R, Verhaeghe J, Mathieu C, Nobels F. Differences in pregnancy outcomes and characteristics between insulin- and diet-treated women with gestational diabetes. BMC Pregnancy Childbirth. 2015;15:271
  11. Bakiner O, Bozkirli E, Ozsahin K, Sariturk C, Ertorer E. Risk factors that can predict antenatal insulin need in gestational diabetes. J Clin Med Res. 2013;5:381-388
  12. Cheng YW, Chung JH, Kurbisch-Block I, Inturrisi M, Shafer S, Caughey AB. Gestational weight gain and gestational diabetes mellitus: Perinatal outcomes. Obstet Gynecol. 2008;112(5):1015-1022
  13. World Health Organization. WHO fact sheet on overweight and obesity. Updated October 2017. (Accessed December 8, 2017, at http://www.who.int/mediacentre/factsheets/fs311/ en/.
  14. Cohen J. Statistical power analysis for the behavioral sciences, 2th Edition, New York, Routledge, 1998
  15. Society of Maternal-Fetal Medicine (SMFM) Publications Committee. Electronic address: [email protected]. SMFM Statement: Pharmacological treatment of gestational diabetes. Am J Obstet Gynecol. 2018;218(5):B2-B4
  16. Mitra S, Nayak PK, Sahoo J, Mathew A, Padma A, Kamalanathan S, Agrawal S. Predictors for antenatal insulin requirements in gestational diabetes. Gynecol Endocrinol. 20